Lexaria Bioscience Valuation
| LEXX Stock | USD 2.13 0.02 0.93% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Lexaria Bioscience Corp secures a last-minute Real Value of $3.33 per share. The latest price of the firm is $2.13. Our model forecasts the value of Lexaria Bioscience Corp from analyzing the firm fundamentals such as Shares Outstanding of 17.45 M, return on equity of -0.71, and Operating Margin of (20.75) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lexaria Bioscience's valuation include:
Price Book 3.7069 | Enterprise Value 29.2 M | Enterprise Value Ebitda (7.22) | Price Sales 91.2928 | Enterprise Value Revenue 70.9463 |
Undervalued
Today
Please note that Lexaria Bioscience's price fluctuation is risky at this time. Calculation of the real value of Lexaria Bioscience Corp is based on 3 months time horizon. Increasing Lexaria Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lexaria Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lexaria Stock. However, Lexaria Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.13 | Real 3.33 | Target 7.0 | Hype 2.15 |
The intrinsic value of Lexaria Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lexaria Bioscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lexaria Bioscience Corp helps investors to forecast how Lexaria stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lexaria Bioscience more accurately as focusing exclusively on Lexaria Bioscience's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lexaria Bioscience's intrinsic value based on its ongoing forecasts of Lexaria Bioscience's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lexaria Bioscience's closest peers.
Lexaria Bioscience Cash |
|
Lexaria Valuation Trend
Analysing the historical paterns of Lexaria Bioscience's enterprise value and its market capitalization is a good way to estimate and gauge the value of Lexaria Bioscience Corp over time and is usually enough for investors to make rational market timing decisions.
Lexaria Revenue by Product
Lexaria Bioscience Total Value Analysis
Lexaria Bioscience Corp is now anticipated to have valuation of 29.16 M with market capitalization of 37.52 M, debt of 163.97 K, and cash on hands of 7.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lexaria Bioscience fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.16 M | 37.52 M | 163.97 K | 7.34 M |
Lexaria Bioscience Investor Information
The book value of the company was now reported as 0.64. The company recorded a loss per share of 0.44. Lexaria Bioscience Corp last dividend was issued on the 12th of January 2021. The entity had 1:30 split on the 12th of January 2021. Based on the measurements of operating efficiency obtained from Lexaria Bioscience's historical financial statements, Lexaria Bioscience Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Lexaria Bioscience Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lexaria Bioscience has an asset utilization ratio of 7.33 percent. This suggests that the Company is making $0.0733 for each dollar of assets. An increasing asset utilization means that Lexaria Bioscience Corp is more efficient with each dollar of assets it utilizes for everyday operations.Lexaria Bioscience Ownership Allocation
Lexaria Bioscience Corp maintains a total of 17.45 Million outstanding shares. Lexaria Bioscience Corp secures 7.0 % of its outstanding shares held by insiders and 6.0 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lexaria Bioscience Profitability Analysis
The company reported the previous year's revenue of 226.21 K. Net Loss for the year was (6.71 M) with profit before overhead, payroll, taxes, and interest of 183.56 K.About Lexaria Bioscience Valuation
Our relative valuation model uses a comparative analysis of Lexaria Bioscience. We calculate exposure to Lexaria Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lexaria Bioscience's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 223.9 K | 212.9 K | |
| Pretax Profit Margin | (1.71) | (1.79) | |
| Operating Profit Margin | 0.27 | 0.28 | |
| Net Loss | (1.71) | (1.79) | |
| Gross Profit Margin | 0.28 | 0.29 |
Lexaria Bioscience Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 6.6 M |
Lexaria Bioscience Current Valuation Indicators
Valuation refers to the process of determining the present value of Lexaria Bioscience Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Lexaria we look at many different elements of the entity such as Lexaria's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lexaria Bioscience, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lexaria Bioscience's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lexaria Bioscience's worth.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.